|
|
| |
Comparison of the Efficacy and Tolerability of Herbal Medicines with 5-aminosalisylates in Inflammatory Bowel Disease: A Meta-analysis of Placebo Controlled Clinical Trials Involving 812 Patients |
|
Roja Rahimi,
Shekoufeh Nikfar and Mohammad Abdollahi |
Abstract:
The use of herbal medicine for the management of Inflammatory
Bowel Disease (IBD) is increasing. The aim of the present study is to compare
the efficacy and tolerability of herbal medicines with 5-aminosalicylates (5-ASAs)
in IBD by conducting a meta-analysis. For this purpose, electronic databases
were searched for studies comparing efficacy and/or tolerability of herbal medicines
with 5-ASAs in different types of IBD. The search terms were: “herb” or “plant”
or “herbal” and “inflammatory bowel disease”. Data were collected from 1966-2013
(up to Feb). The “clinical response”, “clinical remission”, “endoscopic response”,
“endoscopic remission”, “histological response”, “histological remission”, “relapse”,
“any adverse events” and “serious adverse events” were the key outcomes of interest.
Eight placebo controlled clinical trials met criteria and were included. Comparison
of herbal medicine with 5-ASAs yielded the following results: a significant
Relative Risk (RR) of 1.28 (95% Confidence Interval (CI): 1.07-1.54, p = 0.008)
for clinical remission; a significant RR of 1.19 (95% CI = 1.01-1.39, p = 0.04)
for clinical response; a non-significant RR of 0.85 (95% CI: 0.34-2.12, p =
0.73) for endoscopic remission; a non-significant RR of 1.14 (95% CI: 0.99-1.3,
p = 0.07) for endoscopic response; a non-significant RR of 0.8 (95% CI: 0.05-13.72)
for histological remission; a non-significant RR of 1.32 (95% CI: 0.64-2.9)
for histological response; a non-significant RR of 1.05 (95% CI: 0.6-1.83, p
= 0.87) for relapse; a non-significant RR of 1.31 (95% CI: 0.8-2.14, p = 0.28)
for any adverse events; and a non-significant RR of 1.8 (95% CI: 0.13-24.5,
p = 0.66) for serious adverse events. Overall, the efficacy and tolerability
of herbal medicines in IBD is comparable to 5-ASAs, but the evidence is too
limited to make any confident conclusion. Further high quality, large controlled
trials are still needed.
|
|
|
PDF
Fulltext
XML
References
Citation
Report Citation
|
|
|
|
| RELATED ARTICLES: |
|
|
|
|
|
|
|
|
|
|
|
|
How to cite this article:
Roja Rahimi, Shekoufeh Nikfar and Mohammad Abdollahi, 2013. Comparison of the Efficacy and Tolerability of Herbal Medicines with 5-aminosalisylates in Inflammatory Bowel Disease: A Meta-analysis of Placebo Controlled Clinical Trials Involving 812 Patients. International Journal of Pharmacology, 9: 227-244.
DOI: 10.3923/ijp.2013.227.244
URL: https://scialert.net/abstract/?doi=ijp.2013.227.244
|
|
|
|
|
| COMMENT ON THIS PAPER |
|
|
